NCT07242417RecruitingEarly phase 1
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
A Preliminary Clinical Study of TC-G203 for Patients With GPC3-Positive Recurrent/Metastatic Solid Tumors
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 17 Nov 2025
- Start date
- 18 Dec 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Beijing GoBroad Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07242417
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 30
- From 18 Dec 2025 to the primary completion date, 31 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior cell or gene therapy.
Other illness
- Primary CNS malignancy or uncontrolled CNS metastases.
- Other malignancies within 5 years
- Active autoimmune disease or history of autoimmune disease.
- Immunodeficiency, including HIV positivity
- Bleeding disorders (inherited or acquired).
- Clinically significant cardiovascular disease.
- Active infection (including tuberculosis, hepatitis C, syphilis).
- Severe systemic or psychiatric illness.
- Severe drug hypersensitivity history.
Other
- Pregnant or breastfeeding women.
- Investigator-assessed unsuitability for trial participation. -
Who the study is looking for
- Participants must voluntarily provide written informed consent.
- Aged 18-75 years (inclusive).
- Life expectancy ≥ 12 weeks.
- ECOG performance status 0-1.
- Failed or unsuitable for standard therapy.
- At least one measurable lesion per RECIST 1.1.
- GPC3-positive tumor confirmed by immunohistochemistry.
- Adequate organ and bone marrow function.
- Effective contraception required for participants of childbearing potential.
- Adequate venous access for leukapheresis.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing GoBroad Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
| GoBroad Healthcare Group Coordinator of this site? Confirm its status | Beijing | China | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.